Characteristics and prognostic implications of peripheral blood lymphocyte subsets in patients with anti-MDA5 antibody positive dermatomyositis-interstitial lung disease

被引:6
|
作者
Ren, Fang-Ping [1 ]
Chen, Qi [1 ]
Yao, Shan-Shan [2 ]
Feng, Lin [3 ]
Xue, Xin-Ying [1 ]
Zhao, Wei-Chao [4 ]
Wang, Dong [3 ]
Zhao, Zhi-Ling [3 ]
Gu, Si-Wei [5 ]
Li, Ting [3 ]
Shen, Ya-Wen [1 ]
Gao, Lan [1 ]
Zang, Xue-Lei [1 ]
Bao, Xin-Yu [6 ]
Tong, Zhao-Hui [3 ]
机构
[1] Capital Med Univ, Beijing Shijitan Hosp, Beijing, Peoples R China
[2] Univ Pittsburgh, Pittsburgh, PA USA
[3] Capital Med Univ, Beijing Chao Yang Hosp, Beijing, Peoples R China
[4] PLA Strateg Support Force Med Ctr, Beijing, Peoples R China
[5] Capital Med Univ, Xuanwu Hosp, Beijing, Peoples R China
[6] Weifang Med Coll, Weifang, Peoples R China
关键词
Anti-melanoma differentiation-associated gene 5; Dermatomyositis; Interstitial lung disease; Lymphocyte subsets; Prognostic; MYOSITIS-SPECIFIC AUTOANTIBODIES; AMYOPATHIC DERMATOMYOSITIS; POLYMYOSITIS; PNEUMONIA; RISK;
D O I
10.1186/s12890-023-02706-y
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Objectives To examine the characteristics of blood lymphocyte subsets in dermatomyositis-interstitial lung disease (DM-ILD) inflicted patients with positive anti-melanoma differentiation-associated gene 5 (anti-MDA5), as well as its prognosis value in this set of patients.Methods Data were retrospectively collected from 253 DM-ILD patients from three hospitals in China between January 2016 to January 2021. Patients were grouped into anti-MDA5 antibody positive group (MDA5(+) DM-ILD) and anti-MDA5 antibody negative group (MDA5(-) DM-ILD) based on myositis-specific autoantibody test results. Demographic characteristics, lymphocyte subsets patterns and other clinical features were compared between the two groups. The association of lymphocyte subsets with 180-day mortality was investigated using survival analysis in MDA5(+) DM-ILD.Results Out of 253 eligible patients with DM-ILD, 59 patients were anti-MDA5(+) and 194 were anti-MDA5(-). Peripheral blood lymphocyte count, CD3(+) count, percentage of CD3(+), CD3(+)CD4(+) count, and CD3(+)CD8(+) count was lower in MDA5(+) DM-ILD than in MDA5(-) DM-ILD- (all P < 0.001) as well as CD3(-)CD19(+) count (P = 0.04). In MDA5(+) DM-ILD, CD3(+)CD8(+) count <= 49.22 cell/mu L (HR = 3.81, 95%CI [1.20,12.14]) and CD3-CD19(+) count <= 137.64 cell/mu L (HR = 3.43, 95%CI [1.15,10.24]) were independent predictors of mortality. CD3(+)CD8(+) count <= 31.38 cell/mu L was associated with a higher mortality risk in all DM-ILD patients (HR = 8.6, 95%CI [2.12,31.44]) after adjusting for anti-MDA5 and other clinical characteristics.Conclusion Significant lymphocytes decrease was observed in MDA5(+) DM-ILD patients. CD3(+)CD8(+) cell count was associated with worse prognosis in both MDA5(+) DM-ILD and all DM-ILD patients.
引用
收藏
页数:10
相关论文
共 50 条
  • [11] The characteristics of lymphocytes in patients positive for anti-MDA5 antibodies in interstitial lung disease
    Huang, Wenhan
    Ren, FeiFeng
    Luo, Lei
    Zhou, Jun
    Huang, Dongmei
    Pan, Zhuma
    Tang, Lin
    RHEUMATOLOGY, 2020, 59 (12) : 3886 - 3891
  • [12] Tofacitinib in interstitial lung disease complicated with anti-MDA5 antibody-positive dermatomyositis: A literature review
    Takanashi, Satoshi
    Kaneko, Yuko
    Takeuchi, Tsutomu
    MODERN RHEUMATOLOGY, 2022, 32 (01) : 231 - 237
  • [13] Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis
    Gono, Takahisa
    Sato, Shinji
    Kawaguchi, Yasushi
    Kuwana, Masataka
    Hanaoka, Masanori
    Katsumata, Yasuhiro
    Takagi, Kae
    Baba, Sayumi
    Okamoto, Yuko
    Ota, Yuko
    Yamanaka, Hisashi
    RHEUMATOLOGY, 2012, 51 (09) : 1563 - 1570
  • [14] Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease
    Ye, Yan
    Fu, Qiong
    Wang, Ran
    Guo, Qiang
    Bao, Chunde
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2019, 33 (08)
  • [15] RAPIDLY PROGRESSIVE INTERSTITIAL LUNG DISEASE DUE TO ANTI-MDA5 ANTIBODY WITHOUT DERMATOMYOSITIS
    Qadri, Anum N.
    Jimenez, Javier Blanco
    CHEST, 2024, 166 (04) : 3367A - 3368A
  • [16] HRCT in accessing of interstitial lung disease in dermatomyositis with positive expression of anti-MDA5 autoantibody
    Diao, L.
    Chen, M.
    Zhu, X.
    Xue, K.
    Cao, H.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (05) : S1 - S1
  • [17] Anti-MDA5 antibody-positive dermatomyositis with lethal progressive interstitial lung disease and advanced gastric cancer
    Toshifumi Yamaoka
    Chie Doi
    Akinori Yokomi
    Atsushi Tanemura
    Hiroyuki Murota
    Mamori Tani
    Hiroko Saruban
    Yasuhito Hamaguchi
    Manabu Fujimoto
    Ichiro Katayama
    European Journal of Dermatology, 2014, 24 : 490 - 491
  • [18] Anti-MDA5 antibody-positive dermatomyositis with lethal progressive interstitial lung disease and advanced gastric cancer
    Yamaoka, Toshifumi
    Doi, Chie
    Yokomi, Akinori
    Tanemura, Atsushi.
    Murota, Hiroyuki
    Tani, Mamori
    Saruban, Hiroko
    Hamaguchi, Yasuhito
    Fujimoto, Manabu
    Katayama, Ichiro
    EUROPEAN JOURNAL OF DERMATOLOGY, 2014, 24 (04) : 490 - 491
  • [19] Efficacy of tofacitinib for slowly progressive interstitial lung disease in a patient with anti-MDA5 antibody-positive dermatomyositis
    Takatani, Ayuko
    Koga, Tomohiro
    Fujita, Yuya
    Fukui, Shoichi
    Endo, Yushiro
    Shimizu, Toshimasa
    Kawakami, Atsushi
    CLINICAL IMMUNOLOGY, 2020, 215
  • [20] Anti-MDA5 antibody-positive dermatomyositis with rapidly progressive interstitial lung disease: report of two cases
    Mehta, Asmita A.
    Paul, Tisa
    Cb, Mithun
    Haridas, Nithya
    BMJ CASE REPORTS, 2021, 14 (04)